Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Flupirtine
Foxp3(+) Treg cells in the inflamed CNS are insensitive to IL-6-driven IL-17 production.
EMD Serono Takes on Exclusive Promotion of Rebif® (interferon beta-1a) in the US
Astrocyte-derived lactosylceramide implicated in multiple sclerosis.
Multiple Sclerosis.
Statement on a nonproprietary name adopted by the USAN Council
Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci.
Remote Physical Activity Monitoring in Neurological Disease: A Systematic Review.
Blocking mitochondrial calcium release in Schwann cells prevents demyelinating neuropathies.
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.
Spectrum of nontraumatic myelopathies in Ethiopian patients: hospital-based retrospective study.
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.
Monoclonal antibodies in MS: mechanisms of action.
Genzyme reports positive top-line results of TOWER, a pivotal phase III trial for AUBAGIO(TM*) (teriflunomide) in relapsing multiple sclerosis
Studying both sexes: a guiding principle for biomedicine.
US and EU regulatory authorities accept PLEGRIDY™ (peginterferon beta-1a) marketing applications for review
Adaptive autoimmunity and Foxp3-based immunoregulation in zebrafish.
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial.
Individualized quality of life of severely affected multiple sclerosis patients: practicability and value in comparison with standard inventories.
Teriflunomide for multiple sclerosis.
Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function.
A much-needed focus on progression in multiple sclerosis.
Pervasive Axonal Transport Deficits in Multiple Sclerosis Models.
Molecular characterization of a peripheral receptor for cannabinoids.
Increased incidence of central nervous system hemorrhages in patients with secondary acute promyelocytic leukemia after treatment of multiple sclerosis with mitoxantrone?

Pages